New study tracks growth in kids with rare disease on enzyme therapy

NCT ID NCT02455622

First seen Apr 05, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This study followed 21 children with Hunter Syndrome who started treatment with Elaprase before age 6. Researchers measured changes in height and weight over time to see how the drug affected growth. The study also monitored safety and compared results to untreated patients from a registry.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Chulalongkorn University

    Bangkok, 10330, Thailand

  • Hospital Infantil Dr Robert Reid Cabral

    Santo Domingo, 10101, Dominican Republic

  • Hospital Kuala Lumpur

    Kuala Lumpur, 50586, Malaysia

  • Mother and Child Health Care Institute of Serbia Dr Vukan Cupic

    Belgrade, 11000, Serbia

  • National Pediatrics Hospital

    Hanoi, Vietnam

  • Philippine General Hospital

    Manila, 1000, Philippines

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, 55131, Germany

Conditions

Explore the condition pages connected to this study.